Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,539,672
  • Shares Outstanding, K 95,688
  • Annual Sales, $ 2,459 M
  • Annual Income, $ -881,710 K
  • 60-Month Beta 0.63
  • Price/Sales 6.66
  • Price/Cash Flow N/A
  • Price/Book 4.58
Trade BGNE with:

Options Overview Details

View History
  • Implied Volatility 43.74% ( +3.14%)
  • Historical Volatility 40.39%
  • IV Percentile 32%
  • IV Rank 26.43%
  • IV High 61.41% on 02/15/24
  • IV Low 37.39% on 11/30/23
  • Put/Call Vol Ratio 0.93
  • Today's Volume 674
  • Volume Avg (30-Day) 182
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 3,307
  • Open Int (30-Day) 2,830

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -2.25
  • Number of Estimates 5
  • High Estimate -1.42
  • Low Estimate -2.73
  • Prior Year -3.64
  • Growth Rate Est. (year over year) +38.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
126.97 +36.14%
on 04/19/24
176.00 -1.79%
on 05/17/24
+40.99 (+31.09%)
since 04/17/24
3-Month
126.97 +36.14%
on 04/19/24
184.80 -6.47%
on 03/13/24
+24.62 (+16.61%)
since 02/16/24
52-Week
126.97 +36.14%
on 04/19/24
245.74 -29.66%
on 05/22/23
-58.15 (-25.17%)
since 05/17/23

Most Recent Stories

More News
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma

/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...

BGNE : 172.85 (+1.06%)
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib)

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...

BGNE : 172.85 (+1.06%)
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

These five biotech companies could have a lot of room to run.

AMGN : 312.47 (-0.71%)
ARGX : 365.81 (-2.87%)
BGNE : 172.85 (+1.06%)
CRSP : 56.22 (+0.99%)
IMVT : 30.70 (-2.48%)
7 Best Cancer Stocks to Invest in Now

The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.

EXEL : 20.91 (-1.51%)
GILD : 67.72 (-0.21%)
NVS : 102.57 (-0.12%)
ON : 73.17 (+0.23%)
PFE : 28.64 (-0.97%)
MDCO : 84.90 (-0.07%)
MRK : 131.19 (+0.24%)
KURA : 22.17 (-3.52%)
AZN.LN : 12,110.002 (-0.46%)
BGNE : 172.85 (+1.06%)
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 67.72 (-0.21%)
AMGN : 312.47 (-0.71%)
BMY : 44.03 (-0.18%)
NVS : 102.57 (-0.12%)
BGNE : 172.85 (+1.06%)
JSPR : 23.02 (+0.77%)
VIGL : 3.52 (-0.56%)
ALVR : 0.7754 (+3.19%)
RCUS : 16.90 (-3.21%)
FLACU : 9.50 (+2.48%)
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BGNE : 172.85 (+1.06%)
BGNE LOSS ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

BGNE : 172.85 (+1.06%)
Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a Bruton's...

BGNE : 172.85 (+1.06%)
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib),...

BGNE : 172.85 (+1.06%)
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones....

BGNE : 172.85 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

See More

Key Turning Points

3rd Resistance Point 182.22
2nd Resistance Point 179.11
1st Resistance Point 175.98
Last Price 172.85
1st Support Level 169.74
2nd Support Level 166.63
3rd Support Level 163.50

See More

52-Week High 245.74
Fibonacci 61.8% 200.37
Fibonacci 50% 186.35
Last Price 172.85
Fibonacci 38.2% 172.34
52-Week Low 126.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar